UTIs are not listed as a common or uncommon side effect in the Summary of Product Characteristics, and clinical trials have not demonstrated a statistically significant increase in UTI incidence compared to placebo
Each plan begins with advanced diagnostics, including InBody 580 composition analysis , and may include peptide protocols , GLP-1 support with Semaglutide or Tirzepatide , nutrition counseling , detox strategies , and hormone optimization
These are anecdotal, but the pattern is consistent with complaints filed against other 503A compounders operating at high volume during the GLP-1 demand surge of 2023 to 2025
Heres what to aim for: Be sure to take rest days to allow your body to recover and avoid overtraining
If constipation persists, discuss it with your WeightCare physician during your refill check-in
That result immediately placed retatrutide ahead of every other published GLP-1-class compound at comparable follow-up, including tirzepatide in SURMOUNT-1 at the matched timepoint